TrialThe lancet. HIV2022

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.

Shabir A Madhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.